Katherine Green - July 9, 2025 Most opposed companies at the EPO in 2024 Opposition activity at the European Patent Office is often a strong indicator of a technology’s ...
Adam Gregory - July 4, 2025 Mewburn Ellis is proud to have worked on 24 of the 100 top-selling pharmaceuticals of 2024 Mewburn Ellis works with some of the world’s most important pharmaceuticals and biologics across a ...
Katherine Green - June 30, 2025 Most opposed patents of 2024 The list is, again, dominated by patents for therapeutic treatments, although the trends seen last ...
Sarah Harvey - June 25, 2025 Combatting AMR in UTIs Urinary tract infections (UTIs) are among the most common bacterial infections, affecting millions ...
Anthony Judd - December 18, 2024 New EPO sanctions against Russia As reported here, in late June 2024 the European Union (EU) extended their package of sanctions in ...
Rebecca Tollervey - October 28, 2024 Claim Requests found Inadmissible in EPO Appeal Proceedings: What Can Proprietors Do? Since the EPO’s Rule of Procedure of the Boards of Appeal (RPBA) were revised in 2020, parties have ...
Chris Denison - October 14, 2024 No referral to the Enlarged Board of Appeal on the requirement for description amendments In a keenly-awaited decision (T 0056/21) issued today, Technical Board of Appeal 3.3.04 (Pregetter, ...
Tom Furnival - October 8, 2024 Most opposed medical device companies at the EPO 2023 Following on from our recent post on the Most Opposed Companies at the EPO 2023 we’ve broken that ...
Katherine Green - September 17, 2024 Most opposed companies at the EPO 2023 The European Patent Office grants about 100,000 patents per year (EPO Statistics here). The grant ...
Emily Hayes - September 6, 2024 Preparing your patent for success in EPO opposition proceedings Emily Hayes shares five simple prosecution tips to strengthen EP patents, ensuring they are in the ...
Alex Galbraith - September 4, 2024 We perform significantly better than the EPO average at oppositions We really are experts when it comes to opposing patents and our enviable success rate speaks for ...
Jeremy Webster - July 26, 2024 Meet the team: Jeremy Webster, Partner, Head of Chemistry As part of our 'meet the team' series, we talk to partner and head of chemistry, Jeremy Webster, ...
Adam Gregory - July 15, 2024 Mewburn Ellis is proud to have worked on 26 of the 100 top-selling pharmaceuticals of 2023 Mewburn Ellis is proud to work with some of the world’s most globally significant pharmaceuticals, ...
Lucy Coe - March 11, 2024 Challenging patents and other clearance actions in Europe Whether it is to remove a current infringement threat, clear the way to reduce the risk in ...
Tom Furnival - February 14, 2024 The major players in the SEP landscape in Europe Next in our series of blogs, we have investigated the major players in the SEP landscape in Europe.
Katherine Green - February 2, 2024 Most opposed patents of 2023 Multiple sclerosis therapies are the subject of two of the most opposed patents of 2023. Novartis’ ...
Emily Hayes - December 20, 2023 Amended Rules of Procedure of the EPO Boards of Appeal are coming into force on 1 January 2024 The EPO Boards of Appeal have now published their amended Rules of Procedure and these will be ...
Tom Furnival - December 19, 2023 How does declaring a patent or application as “essential to a standard” affect the pre-grant experience of an application? – Part 3 This article continues our series of blogs investigating whether or not declaring your patent or ...
Lucy Coe - December 4, 2023 EPO will accelerate oppositions when there are parallel UPC infringement or revocation proceedings The EPO have announced in the November 2023 Official Journal that they will accelerate opposition ...
Sean Constable - November 30, 2023 Practical tips for EPO appeal proceedings under the new, stricter rules: 5 key takeaways from a recent EPO conference In 2020 the EPO revised the rules that govern the procedure at the EPO Boards of Appeal. As we ...
Katherine Green - November 13, 2023 Most opposed patents of 2022 As with CRISPR, patents directed to Nobel Prize-winning technologies are viewed as extremely ...
Simon Kremer - October 13, 2023 The EPO’s Enlarged Board of Appeal decides how the EPO should assess entitlement to priority The Enlarged Board of Appeal of the EPO has now issued its long-awaited answers to the legal ...
David Brooks - July 19, 2023 Mewburn Ellis is proud to work on 18 of the 50 top-selling pharmaceuticals of 2022 Last year we reported the unprecedented growth of the innovative pharmaceuticals industry in 2021 ...
Callum McGuinn - February 8, 2023 Meet the team: Callum McGuinn, Partner and Patent Attorney in the Chemistry team, London As part of our 'meet the team' series, we talk to Callum McGuinn about his journey to becoming a ...
Julie Carlisle - February 5, 2023 Meet the team: Julie Carlisle, Partner, Patent Attorney and Litigator in the Chemistry team, London As part of our 'meet the team' series, we talk to Julie Carlisle about her journey to becoming a ...
Emma Graham - February 1, 2023 Should I file third party observations? A study of the consequences of filing third party observations (TPOs) in the MedTech sector and the ...
Eleanor Maciver - January 24, 2023 Meet the team: Eleanor Maciver, Partner and Patent Attorney in the Chemistry team, Cambridge As part of our 'meet the team' series, we talk to Eleanor Maciver about her journey to becoming a ...
Jonathan Wills - November 23, 2022 Opposition and examination oral proceedings by videoconference (ViCo) now as standard In response to the significant travel restrictions that were in place across Europe during the ...
Simon Kiddle - November 16, 2022 Positive feedback on oral proceedings in oppositions carried out by videoconference In September, the EPO commissioned a survey about their opposition procedure, in particular asking ...
Katherine Green - November 7, 2022 Eight days – the longest ever opposition hearing at the EPO? The EPO Opposition Division just issued its decision on European Patent 2 188 302 following an ...
Paul Dunne - November 1, 2022 Meet the team: Paul Dunne, Partner and Patent Attorney in the Chemistry team, Bristol As part of our 'meet the team' series, we talk to Paul Dunne about his journey to becoming a patent ...
Emily Hayes - August 5, 2022 We perform significantly better than the EPO average at oppositions We really are experts when it comes to opposing patents and our enviable success rate speaks for ...
Katherine Green - July 28, 2022 Most opposed patents of 2021 When we reviewed our list of the most opposed European patents of 2021, we found that the patent at ...
Adam Gregory - July 22, 2022 Mewburn Ellis is proud to work on 19 of the 50 top-selling pharmaceuticals of 2021 2021 was a year of unprecedented success for the biotech and pharmaceutical industries, with the ...
Simon Parry - May 25, 2022 Meet the team: Simon Parry, Partner, Patent Attorney, Engineering, Manchester As part of our 'meet the team' series, we talk to Simon Parry about his journey to becoming a ...
Emma Graham - May 18, 2022 Meet the team: Emma Graham, Partner, Patent Attorney, Engineering, London As part of our 'meet the team' series, we talk to Emma Graham about her journey to becoming a ...
Stephen Gill - May 11, 2022 Meet the Team: Stephen Gill, Partner, Patent Attorney, Engineering, Cambridge As part of our 'meet the team' series, we talk to Stephen Gill about his journey to becoming a ...
Emily Hayes - April 7, 2022 EPO extends pilot for oral proceedings in opposition by videoconference to 31 December 2022 On 6 April 2022, the EPO issued a notice extending its pilot project for conducting oral ...
Florian Zobel - March 30, 2022 2022 changes to EPO Guidelines: highlights With the 2021 changes to the examination guidelines, the EPO changed its schedule for issuing ...
Katherine Green - January 26, 2022 A guide to EPO opposition proceedings by videoconference EPO oppositions by videoconference only became possible relatively recently, in April 2020. In 2021 ...
Emily Hayes - November 24, 2021 EPO extends pilot for oral proceedings in opposition by videoconference to 31 May 2022 On 23 November 2021, the EPO issued a notice extending its pilot project for conducting oral ...
Emily Hayes - October 29, 2021 Videoconference oral proceedings: Enlarged Board of Appeal issues reasons for its decision in G 1/21 The Enlarged Board has now issued its full written decision in G 1/21 relating to videoconference ...
Katherine Green - September 6, 2021 Most opposed patents of 2020 Every year at the EPO about 3000-4000 patents are opposed. This figure represents only about 3-4% ...
Emily Hayes - July 21, 2021 Board of Appeal oral proceedings may be held by videoconference (ViCo) in an emergency On 16 July 2021, the Enlarged Board of Appeal confirmed that Board of Appeal oral proceedings may ...
Helen Bower - May 10, 2021 EPO Opposition Trends in Engineering, Electronics and Software Special Report In autumn 2020, we analysed more than 8000 opposition cases filed at the European Patent Office ...
Emma Graham - May 7, 2021 Engineering oppositions: is there such thing as a “disguised method claim”? Case - T 1798/08
Stephen Gill - May 6, 2021 We helped determine the meaning of “technical feature” Case - T 0258/03 Our extensive arguments in relation to whether a feature is ‘technical’ have ...
Matthew Naylor - May 5, 2021 Case review: what can be considered as prior art when assessing inventive step? Case - T 0211/06 In the decision T 0211/06 from the EPO Board of Appeal (BoA), Engineering partner ...
Stephen Gill - May 3, 2021 Engineering oppositions: what is considered to be an implicit disclosure in a patent application? Case - T2541/11 This decision provides guidance and clarification in three key areas of EP law:
Sofia Arenal - February 3, 2021 Practical considerations for evidence at the UKIPO Since it is no longer possible to cover the UK by filing a trade mark application at the EU ...
Kate O'Rourke - December 16, 2020 Brexit has happened - what you need to know about the impact on trade marks Kate O’Rourke sets out the principles for UK and EU trade mark protection which came into force ...
Kate O'Rourke - November 20, 2020 UKIPO confirms new ‘Address for Service’ rules CITMA is celebrating a major victory on Brexit in the wake of the UKIPO’s latest “address for ...
Christopher Casley - November 13, 2020 Videoconference Oral Proceedings for EPO Oppositions – an Update The EPO has announced changes to the Pilot Project for Video Conference (ViCo) Oral Proceedings ...
Christopher Casley - November 13, 2020 EPO Zooming to catch-up UPDATE 6 APRIL 2022: On 6 April 2022, the EPO issued a notice extending its pilot project for ...
Katherine Green - August 21, 2020 Most Opposed Patents of 2019 The four thousand or so European patents that are opposed every year represent only about 3% of all ...
Simon Kiddle - August 20, 2020 Oppositions & Appeals: we helped clear a new path to patenting dosage regimes Case 10 – T 1020/03 (EPO Board of Appeal, 29 October 2004)
Seán Walton - July 24, 2020 Oppositions & Appeals: novelty of a patient sub-population Case 9 – T 734/12 (EPO Board of Appeal, 17 May 2013)
Simon Kiddle - June 29, 2020 Oppositions & Appeals: we helped determine the meaning of “surgery” Case 8 – T 1695/07 (EPO Board of Appeal, 28 September 2011)
Simon Kiddle - May 18, 2020 Oppositions & Appeals: We helped shape the debate on medical use claim patentability Case 7 – T 879/12 (EPO Board of Appeal, 27 August 2014)
Simon Kiddle - April 27, 2020 Oppositions & Appeals: We moved the conversation on animal involvement Case 6 – T 1262/04 (EPO Board of Appeal, 13 July 2012)
Seán Walton - March 12, 2020 Oppositions & Appeals: We set the standard for the strawman Case 5 - T 649/92 (EPO Enlarged Board of Appeal, 2 July 1996)
Katherine Green - February 24, 2020 EPO streamlining: the opposition timeline tightens Our analysis of patent oppositions has revealed that early action has become imperative for ...
Richard Clegg - February 12, 2020 Oppositions & Appeals: we opened the door for different types of data to support a medical use Case 4 - T 801/06 (EPO Board of Appeal, 4 March 2009)
Simon Kiddle - January 29, 2020 Oppositions & Appeals: We made the case for a new technical effect Case 3 - T 1642/06 (EPO Board of Appeal, 23 August 2007)
Richard Clegg - November 15, 2019 Meet the team: Richard Clegg, Partner, European Patent Attorney, Patent Attorney Litigator As part of our 'meet the team' series, we talk to Richard Clegg about his journey to becoming a ...
Maria Hall - November 14, 2019 New report launched: EPO Opposition Trends in the Life Sciences Sector Our new research has revealed several recent patterns regarding the European Patent Office ...
Katherine Green - November 14, 2019 EPO oppositions: Nine key questions answered Mewburn Ellis has dug deep into a decade of EPO life sciences' decisions to discover fresh insights ...
Chris Denison - November 12, 2019 Meet the team: Chris Denison, Partner, European Patent Attorney As part of our 'meet the team' series, we talk to Chris Denison about his journey to becoming a ...
Seán Walton - November 11, 2019 Oppositions a case to remember: we forced a fuller view of technical features Case 1 – T 1859/08 ( EPO Board of Appeal, 5 June 2016)
Simon Kiddle - November 8, 2019 Meet The Team: Simon Kiddle, Partner, European Patent Attorney As part of our 'meet the team' series, we talk to Simon Kiddle about his journey to becoming a ...
Katherine Green - November 5, 2019 Meet The Team: Katherine Green, Partner, European Patent Attorney As part of our 'meet the team' series, we talk to Katherine Green about her journey to becoming a ...
Katherine Green - October 30, 2019 Oppositions - a case to remember. Flexibility around added matter Case 2 – T 0099/13 (EPO Board of Appeal, 14 January 2016)
Emily Hayes - October 28, 2019 Meet The Team: Emily Hayes, Partner, European Patent Attorney As part of our 'meet the team' series, we talk to Emily Hayes about her journey to becoming a ...
